Bacteria of the same species wage war on human skin, and that intraspecies competition sharply restricts which strains can coexist within a single microbiome, according to a study published in Nature.

The finding reframes how dermatology researchers should read the skin microbiome. Most clinical work to date — from eczema flares to acne and rosacea — has characterized microbial communities at the species level. The Nature paper argues that the real action happens one level down, among closely related strains of the same species competing for the same niche on the skin surface.

Why strain identity matters

Two strains of Cutibacterium acnes or Staphylococcus epidermidis can carry nearly identical species labels while deploying very different arsenals: distinct antimicrobial compounds, different metabolic capacities, and different interactions with host immunity. When such strains occupy the same patch of skin, the study finds, they actively antagonize one another. That intraspecies warfare acts as a filter. It prevents the accumulation of many similar strains in one site and instead drives each skin region toward dominance by a limited set of strains.

In practical terms, coexistence is the exception, not the rule. Strains that overlap too closely in resource use and attack each other directly cannot stably share a microhabitat. The result is a skin microbiome structured less like a diverse marketplace of species and more like a set of strain-level territories.

What this means for dermatology

The implications reach into several disease areas where species-level profiling has so far produced mixed results:

• Atopic dermatitis. Studies linking Staphylococcus aureus abundance to eczema severity may mask strain-level differences. If only certain strains can persist on inflamed skin — because they outcompete commensal S. epidermidis strains — then strain identity, not species presence, could be the clinically relevant variable.
• Acne. C. acnes strains differ in their association with disease versus healthy skin. A mechanism that restricts coexistence helps explain why particular lineages dominate pilosebaceous units rather than mixtures of many strains.
• Therapeutic design. Live biotherapeutics and bacteriocin-producing commensals under development for skin disease must survive not just host defenses but local strain-level competition. A candidate organism that works in one patient's skin niche may fail in another patient whose resident strains mount effective counterattack.

The study also carries a caution for diagnostics. Metagenomic profiling that reports species abundances could miss the therapeutic target entirely: a pathobiont strain may be present at low total-species read counts yet poised to dominate once competitors are removed by antibiotics or topical treatment.

A mechanism, not just a pattern

What distinguishes the Nature work from earlier surveys of skin microbial diversity is its mechanistic framing. The authors identify intraspecies antagonism — direct interference competition between conspecific strains — as the process restricting coexistence. This is not merely an observation that skin sites harbor few strains. It is an explanation of why: strains sharing a niche and possessing weapons against each other exclude one another, and the community structure follows.

For researchers building strain-level interventions, such as engineered commensals or strain-targeted phage therapies, the competitive dynamics now documented in the skin setting will shape engraftment, persistence, and dosing. Successful colonization may require either exploiting an empty niche or deliberately displacing a resident strain that actively resists newcomers.

Looking ahead

The paper sets up a clear next question for clinical translational work: whether strain-level exclusion patterns predict disease transitions — for instance, which commensal strain holds a niche before a flare and which pathobiont takes it over. If dermatology moves its microbiome endpoints from species relative abundance to strain occupancy, trial designs for microbiome-directed therapies in eczema, acne, and wound infection will need to account for the warfare happening within a single species name.